Scinovex
articleTop 1% cited

Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

Neuropharmacology · 2006 · Vol. 52(3) · pp. 985–994
Hans RollemaLeslie K. ChambersJ.W. CoeJohn R. GlowaRaymond S HurstLorraine A. LebelYi LuRobert S. MansbachRobert J. MatherCharles C. RovettiSteven B. SandsEric SchaefferDavid W. SchulzF. David TingleyKathryn Williams
Nicotinic Acetylcholine Receptors StudySmoking Behavior and CessationReceptor Mechanisms and SignalingVareniclinePartial agonistPharmacologyNicotineNicotinic agonistSmoking cessationAgonistNicotinic acetylcholine receptorDopamineNucleus accumbens

MeSH terms

VareniclineAnimalsBehavior, AnimalBenzazepinesBrainCell Line, TransformedDopamineDose-Response Relationship, DrugDrug Administration ScheduleHumansMaleMembrane PotentialsNicotineProtein BindingQuinoxalines

Funding

  • Pfizer
Citations
533
FWCI
13.71
field-weighted impact
References
44
Percentile
99%
vs. same field & year
Citations per year
Cited by
Varenicline:  An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Journal of Medicinal Chemistry · 2005 · 930 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid · Scinovex